Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(23):1861; doi:10.1093/jnci/92.23.1861
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 23, 1861, December 6, 2000
© 2000 Oxford University Press

IN THIS ISSUE

Her-2-neu Expression and Prostate Cancer

Increased expression of the receptor tyrosine kinase Her-2-neu is associated with poor prognosis for women with breast or ovarian cancer; however, the association between Her-2-neu expression and prostate cancer has been controversial. Signoretti et al. (p. 1918) evaluated expression of Her-2-neu in untreated, androgen-dependent, and androgen-independent human prostate cancers. Although the Her-2-neu gene was not amplified in prostate cancer, the authors reported that the proportion of tumors expressing Her-2-neu protein was lowest in the untreated cancers, higher in androgen-dependent cancers, and highest in . . . [Full Text of this Article]

Chemoprevention of Gastric Dysplasia in Colombia

Cigarette Smoking and Colorectal Cancer Mortality

Synergistic Cytotoxicity in Solid Tumor Cell Lines

Breast Cancer and Tamoxifen Resistance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?